Literature DB >> 7961220

Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes.

F Minguez1, M L Chiu, J E Lima, R Nique, J Prieto.   

Abstract

Exposure times and serum concentrations in humans after treatment with multiple doses of fluconazole have been studied to measure: (a) the postantifungal effect (PAFE) on Candida albicans, at two concentrations of the drug in the presence or absence of 10% human serum; (b) the activity of low concentrations of the drug on yeasts previously exposed to fluconazole with or without 10% human serum; and (c) the effect of fluconazole pretreatment on the fungicidal activity of leucocytes and serum against C. albicans. Fluconazole showed no PAFE against C. albicans between -0.1 and -0.7 h, but when the assays were performed in the presence of serum, concentration dependent PAFEs were obtained (1.1 h-3.6 h). Pretreated yeasts were more susceptible than untreated yeasts to low concentrations of the drug. The decrease in growth was dependent on the concentration used in pretreatment. Growth delay was also more marked when the yeast cells were tested in the presence of serum. Pretreatment of the growing C. albicans cells with fluconazole increased their vulnerability to killing by leucocytes mainly in the first hour (P < 0.05). These results could partially explain why fluconazole has more activity in vivo than in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961220     DOI: 10.1093/jac/34.1.93

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

2.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Method for measuring postantifungal effect in Aspergillus species.

Authors:  Roxana G Vitale; Johan W Mouton; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.

Authors:  Katsuyuki Maki; Shuji Kaneko
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-03-29       Impact factor: 2.441

5.  In vivo Activity of Copper(II), Manganese(II), and Silver(I) 1,10-Phenanthroline Chelates Against Candida haemulonii Using the Galleria mellonella Model.

Authors:  Rafael M Gandra; Pauraic McCarron; Livia Viganor; Mariana Farias Fernandes; Kevin Kavanagh; Malachy McCann; Marta H Branquinha; André L S Santos; Orla Howe; Michael Devereux
Journal:  Front Microbiol       Date:  2020-03-24       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.